Lixivaptan BALANCE study is a 650-patient Phase III, global, multi-center, randomized, placebo-controlled, double-blind, study of lixivaptan for hyponatremia in patients with heart failure. The primary objective is to evaluate the safety and effectiveness of lixivaptan, when compared to the placebo, in increasing serum sodium from baseline in heart failure patients with hyponatremia. In previous studies, lixivaptan improved blood sodium levels, lowered body weight and increased urine volume. Those studies suggest that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with heart failure, Syndrome of Inappropriate Anti-Diuretic Hormone(SIADH), and Liver Cirrhosis with
Serum-separating tube particles to cause blood to clot quickly. The blood sample may then be centrifuged, allowing the clear serum to be removed for testing. These tubes should be used with care when measuring drug or hormone levels because the drug or hormone may diffuse from the serum into the gel, causing a reduction in measured level. The gel in SST II tubes (which appears slightly less opaque) is supposed to have less effect on drug levels in serum. Serum-separating tube Serum-separating tubes, also known as serum separator tubes or SSTs, are used in medical clinical chemistry tests requiring blood serum. SSTs